Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBIO NASDAQ:INVA NASDAQ:MNKD NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCrescent Biopharma$14.24+4.0%$13.62$10.83▼$63.00$278.39M1.5991,506 shs137,894 shsINVAInnoviva$20.48-2.1%$19.58$16.67▼$22.00$1.29B0.47743,277 shs950,155 shsMNKDMannKind$5.54+3.7%$4.00$3.38▼$7.63$1.70B1.025.09 million shs6.76 million shsNVAXNovavax$7.90+1.4%$7.52$5.01▼$15.22$1.28B2.687.67 million shs5.43 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCrescent Biopharma+4.02%-1.11%+29.45%-98.14%-98.14%INVAInnoviva-2.10%+0.24%+12.24%-5.10%+4.01%MNKDMannKind+3.75%+20.70%+60.12%+26.48%-9.03%NVAXNovavax+1.41%+5.76%+4.22%+6.04%-33.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCrescent Biopharma$14.24+4.0%$13.62$10.83▼$63.00$278.39M1.5991,506 shs137,894 shsINVAInnoviva$20.48-2.1%$19.58$16.67▼$22.00$1.29B0.47743,277 shs950,155 shsMNKDMannKind$5.54+3.7%$4.00$3.38▼$7.63$1.70B1.025.09 million shs6.76 million shsNVAXNovavax$7.90+1.4%$7.52$5.01▼$15.22$1.28B2.687.67 million shs5.43 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCrescent Biopharma+4.02%-1.11%+29.45%-98.14%-98.14%INVAInnoviva-2.10%+0.24%+12.24%-5.10%+4.01%MNKDMannKind+3.75%+20.70%+60.12%+26.48%-9.03%NVAXNovavax+1.41%+5.76%+4.22%+6.04%-33.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBIOCrescent Biopharma 3.33Buy$25.6079.78% UpsideINVAInnoviva 3.00Buy$42.75108.74% UpsideMNKDMannKind 3.25Buy$10.7193.40% UpsideNVAXNovavax 2.13Hold$14.2980.83% UpsideCurrent Analyst Ratings BreakdownLatest CBIO, INVA, NVAX, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025MNKDMannKindOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.009/3/2025MNKDMannKindWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$9.00 ➝ $10.009/2/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.008/28/2025NVAXNovavaxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.008/27/2025CBIOCrescent BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/26/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $8.008/25/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/25/2025CBIOCrescent BiopharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.008/20/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$9.00 ➝ $7.008/11/2025CBIOCrescent BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.008/11/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBIOCrescent Biopharma$10K27,839.20N/AN/A$8.24 per share1.73INVAInnoviva$358.71M3.60$3.42 per share5.98$11.03 per share1.86MNKDMannKind$285.50M5.95$0.14 per share39.92($0.29) per share-19.10NVAXNovavax$682.16M1.88N/AN/A($3.89) per share-2.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBIOCrescent Biopharma-$37.88M-$34.93N/AN/AN/AN/A-106.06%-86.60%N/AINVAInnoviva$23.39M$0.3166.0713.21N/A10.44%18.67%9.92%11/5/2025 (Estimated)MNKDMannKind$27.59M$0.1150.3724.09N/A10.87%-32.60%7.81%11/6/2025 (Estimated)NVAXNovavax-$187.50M$2.283.4698.750.1039.20%-142.33%28.65%11/11/2025 (Estimated)Latest CBIO, INVA, NVAX, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025INVAInnoviva$0.57$0.77+$0.20$0.77$87.10 million$100.28 million8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 million8/6/2025Q2 2025NVAXNovavax-$0.07$0.62+$0.69$0.62$149.19 million$239.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBIOCrescent BiopharmaN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBIOCrescent BiopharmaN/A9.219.21INVAInnoviva0.362.642.44MNKDMannKindN/A2.502.24NVAXNovavax5.932.362.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBIOCrescent Biopharma75.19%INVAInnoviva99.12%MNKDMannKind49.55%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipCBIOCrescent Biopharma4.00%INVAInnoviva2.25%MNKDMannKind2.70%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBIOCrescent Biopharma5019.55 million18.77 millionNo DataINVAInnoviva10063.02 million61.60 millionOptionableMNKDMannKind400306.83 million298.54 millionOptionableNVAXNovavax1,990162.42 million160.80 millionOptionableCBIO, INVA, NVAX, and MNKD HeadlinesRecent News About These CompaniesNovavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 4 at 3:04 PM | seekingalpha.comNuvaxovid® Now Approved in Japan Triggering Takeda Milestone PaymentSeptember 4 at 8:00 AM | prnewswire.comNovavax ‘applauds’ President Trump’s call for available COVID-19 vaccine dataSeptember 4 at 2:44 AM | msn.comNovavax to Participate in the Cantor Global Healthcare ConferenceSeptember 3 at 10:54 AM | finance.yahoo.comOMERS ADMINISTRATION Corp Takes $1.28 Million Position in Novavax, Inc. $NVAXSeptember 3 at 4:59 AM | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Receives $14.29 Consensus PT from AnalystsSeptember 3 at 2:25 AM | americanbankingnews.comOptimistic Outlook on Novavax: Strategic Positioning and Vaccine Developments Drive Buy RatingSeptember 2, 2025 | tipranks.comRafferty Asset Management LLC Sells 80,502 Shares of Novavax, Inc. $NVAXSeptember 2, 2025 | marketbeat.comInvesco Ltd. Boosts Stake in Novavax, Inc. $NVAXSeptember 2, 2025 | marketbeat.comFY2025 Earnings Forecast for Novavax Issued By HC WainwrightSeptember 2, 2025 | marketbeat.comHC Wainwright Comments on Novavax FY2025 EarningsSeptember 2, 2025 | americanbankingnews.comNuveen LLC Purchases New Position in Novavax, Inc. $NVAXSeptember 1, 2025 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Given Consensus Recommendation of "Hold" by BrokeragesSeptember 1, 2025 | marketbeat.comQ3 Earnings Forecast for Novavax Issued By HC WainwrightAugust 31, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Novavax (NASDAQ:NVAX)August 30, 2025 | marketbeat.comKohl’s, Bill.com, Novavax, Jazz, Nvidia: Trending by AnalystsAugust 30, 2025 | tipranks.comHC Wainwright Initiates Coverage on Novavax (NASDAQ:NVAX)August 30, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for Novavax Q3 Earnings?August 30, 2025 | americanbankingnews.comNovavax, Inc. (NVAX) Wins FDA Approval for Nuvaxovid BLAAugust 29, 2025 | finance.yahoo.comRobert Kennedy Jr. Announces End Of FDA Covid Mandates – Clears Moderna, Pfizer, Novavax For High-Risk GroupsAugust 28, 2025 | msn.comNovavax (NVAX) Is Up After FDA Approves Updated Nuvaxovid for Key High-Risk Groups—What's ChangedAugust 28, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBIO, INVA, NVAX, and MNKD Company DescriptionsCrescent Biopharma NASDAQ:CBIO$14.24 +0.55 (+4.02%) As of 09/5/2025 04:00 PM EasternCrescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Innoviva NASDAQ:INVA$20.48 -0.44 (-2.10%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$20.48 0.00 (0.00%) As of 09/5/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.MannKind NASDAQ:MNKD$5.54 +0.20 (+3.75%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.54 0.00 (-0.09%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Novavax NASDAQ:NVAX$7.90 +0.11 (+1.41%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$7.88 -0.03 (-0.32%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
